China pharmaceutical promotion association organized a delegation to Hong Kong to attend the "2018 Hong Kong Biotechnology summit"

Source: China pharmaceutical innovation promotion association March 23, 2018 the "2018 Hong Kong Biotechnology summit" (hereinafter referred to as the "summit") hosted by Hong Kong exchange and Clearing Limited (hereinafter referred to as the "Hong Kong Exchange") was held in the financial hall of the Hong Kong Exchange on March 22, 2018 The summit aims to provide biotechnology companies with channels to communicate with investors, market participants and capital market experts, and jointly build the investment and financing ecosystem of biotechnology in Hong Kong China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China pharmaceutical promotion association") organized more than 20 member enterprises and nearly 40 representatives to attend the meeting in Hong Kong About 600 senior managers, institutional investors, analysts and other market participants of biotechnology companies and industry organizations gathered to conduct in-depth exchanges on hot topics such as the development of global biotechnology, the latest situation of the mainland biotechnology industry and the challenges the industry will face in the future At the opening ceremony, Mr Zhou Songgang, chairman of the Hong Kong stock exchange group, Mr Chen maobo, financial secretary of the Special Administrative Region, Mr Tang Jiacheng, chairman of the securities and Futures Commission, Mr o'dali, chief executive officer and Mr Li Xiaojia, chief executive officer of the Hong Kong Stock Exchange delivered opening speeches respectively At the opening ceremony, he Ruyi, chief scientist of the drug review center of the State Food and Drug Administration (hereinafter referred to as "CFDA"), made an in-depth introduction on how to speed up the review and approval of drugs 2017 is an important period in China's pharmaceutical innovation and development process CFDA joined the International Coordinating Council for technical requirements of human drugs (ICH for short), which has launched the relevant work of applying ICH secondary guiding principles in an all-round way, and China's drug safety standards are officially in line with international standards In October 2017, the opinions of the two offices pointed out the way forward for the reform of China's pharmaceutical review and approval system, which will greatly improve the quality and effectiveness of the reform of the review system He Ruyi, chief scientist, made a keynote report Song Ruilin, executive chairman of China Pharmaceutical Association, made a keynote report entitled "progress and development trend of Biomedical Innovation in the mainland" President Song pointed out that since the 18th National Congress of the Communist Party of China, China's economic development model has shifted from high-speed growth to high-quality development, and the biomedical industry is the key to China's economic transformation and upgrading The relevant policies issued by the government promote the rapid growth of investment and financing in China's biomedical industry The proportion of Chinese pharmaceutical R & D enterprises and pharmaceutical investment institutions in the world market has increased VC / PE financing in the field of health care is active The trend of overseas listing of mainland pharmaceutical enterprises is increasingly obvious Some innovative enterprises also have a very bright performance on NASDAQ With the entry of CFDA into ICH, China's drug review and approval will be in line with international standards Hong Kong Stock Exchange's policy reform on zero profit IPO of biological innovation enterprises undoubtedly has brought a timely spring rain for the coming spring of China's pharmaceutical industry, which can make real good enterprises grow faster and better Song Ruilin, executive chairman, made a keynote report At the invitation of the Hong Kong stock exchange, the China Council for the promotion of drugs organized a panel discussion on "the progress and development trend of Biomedical Innovation in the mainland" Tian Yuan, vice chairman of Pharmaceutical Innovation Investment Committee of China pharmaceutical promotion association and founding partner of Shenzhen Qianhai Yuanming Asset Management Co., Ltd., presided over the discussion Yu Dechao, vice chairman of pharmaceutical research and Development Committee of China pharmaceutical promotion association, Yu Dechao, chairman of Xinda biopharmaceutical Co., Ltd., Yang Dajun, vice chairman of pharmaceutical research and Development Committee of China pharmaceutical promotion association, chairman and CEO of Yasheng Pharmaceutical Co., Ltd., and Kangning Jierui biological Co., Ltd Xu Ting, chief executive officer and founder of biotechnology, respectively, had in-depth and intense discussions on the characteristics and importance of the biotechnology industry in the mainland, the challenges and risks faced by pharmaceutical enterprises in the process of innovation and development, and the gap between the development of the biotechnology industry in China and the United States There are more and more excellent biomedical R & D companies in mainland China They may not be able to generate revenue in the short term, but the return on equity is growing rapidly The Hong Kong Stock Exchange has announced public market consultation on the revision of Listing Rules for innovative companies, facilitating the listing of unprofitable biotechnology enterprises in Hong Kong and further expanding the capital market of Hong Kong This move is of great significance to the research and development of new drugs in China, and will provide a more convenient financing platform for the proposed issuers of biotechnology and create a more dynamic market for Hong Kong Beijing jiakesi new drug R & D Co., Ltd., Baiji Shenzhou (Beijing) Biotechnology Co., Ltd., Hutchison Huangpu Pharmaceutical (Shanghai) Co., Ltd., Shenzhen AoSA Pharmaceutical Co., Ltd., Beihai Kangcheng (Beijing) Pharmaceutical Technology Co., Ltd., Fang en (Tianjin) Pharmaceutical Development Co., Ltd., Beijing nuocheng Jianhua pharmaceutical Technology Co., Ltd., Wuhan Heyuan Biotechnology Co., Ltd Company, Geli Biotechnology (Hangzhou) Co., Ltd., Sichuan Jiuzhang Biotechnology Co., Ltd., LVYE Pharmaceutical Group Co., Ltd., Shanghai Fuhong Hanlin Biotechnology Co., Ltd., Beida Pharmaceutical Co., Ltd., Shenzhen Yifeng Investment Management Enterprise (limited partnership), Haijie investment holding group, Shanghai Lize Investment Management Co., Ltd., Ping An Bank Medical Co., Ltd Representatives of healthy culture and tourism financial business department, DFT capital and other enterprises also attended the summit.